Table 2.
HbA1c changes according to randomisation group (N = 256) and frequency of device use
| Models | Over 1 year | |||||
|---|---|---|---|---|---|---|
| β | 95% CI | p | Δ | 95% CI | ||
| Randomisation group | ||||||
| Control group (CG) | ||||||
| Telemonitoring group (TMG) | − 0.16 | − 0.32; 0.01 | 0.06 | * | − 0.24 | − 0.42; − 0.07 |
| Number of connections (synthesis) | ||||||
| Control group (CG) | ref | − 0.08 | − 0.26; 0.09 | |||
| TMGs− number ≤ median | − 0.08 | − 0.28; 0.13 | 0.45 | − 0.16 | − 0.38; 0.05 | |
| TMGs+ number > median | − 0.23 | − 0.43; − 0.03 | 0.03 | ** | − 0.31 | − 0.53; − 0.10 |
| Number of connections (Nutri-Educ) | ||||||
| Control group | ref | − 0.09 | − 0.26; 0.09 | |||
| TMGn− number ≤ median | − 0.11 | − 0.31; 0.10 | 0.30 | − 0.19 | − 0.40; 0.01 | |
| TMGn+ number > median | − 0.21 | − 0.41; 0.00 | 0.05 | ** | − 0.29 | − 0.51; − 0.07 |
Models adjusted for potential confounding factors defined a priori, taking into account time effect, centre effect and randomisation per stratum. HbA1c value at baseline was 7.75% (95% CI [7.65; 7.85])
With β linear regression coefficients, 95% CI 95% confidence intervals, p p value, m average HbA1c observed at T0 (%) and Δ predicted variation over 1 year
**Significant difference between groups (< 0.05); *difference at the limit of significance (< 0.10)